What happened
Kolmar BioTech reported separate results for FY2025: revenue of US$26M (−13% year on year), an operating loss of US$2.77M (from a profit a year earlier) and a net loss of US$3.89M (from a profit a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$26M |
|---|---|
| Revenue vs a year earlier | −13% |
| Operating profit | −US$2.77M |
| Net income | −US$3.89M |
| Period | FY2025 (separate) |
| Filed | 2026-02-12, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260212900553 → open original filing |
Source: DART. Information only, not investment advice.